Objective: To assess the influence of guideline-adherent vs nonadherent antithrombotic treatment (ATT) on stroke and mortality rates in an atrial fibrillation (AF) primary care population. Patients and Methods: We used the Darlington Registry cohort, which included 105,000 patients from March 31, 2012, through March 31, 2013. Guideline adherence in ATT was assessed against 2014 National Institute for Health and Care Excellence guidelines, which recommend oral anticoagulation for stroke prevention as a default management unless a truly low risk of stroke (CHA 2 DS 2 -VASc¼0 in men and 1 in women) is evident. Results: Of 2259 patients with AF (2.15%), 36.1% were undertreated, 50.8% were guideline adherent, and 13.1% were overtreated. Oral anticoagulation was declined by 5.0% and contraindicated in 8.3%. Of 67 incident strokes (3.0%), 66 (98.5%) occurred in high-risk patients (CHA 2 DS 2 -VASc !2). For the highrisk cohort, 1-year stroke rates were 4.5% (95% CI, 3.2%-6.3%) for undertreatment, 1.9% (95% CI, 1.2%-2.9%) for guideline adherence, and 7.2% (95% CI, 4.4%-11.6%) for overtreatment; corresponding mortality rates were 16.1% (95% CI, 13.6%-19.0%), 8.0% (95% CI, 6.5%-9.8%), and 8.2% (95% CI, 5.2%-12.7%), respectively. On multivariable analysis, both undertreatment and overtreatment of high-risk patients were associated with significant increases in stroke rates (odds ratio [OR]¼2.32; 95% CI, 1.30-3.14; P¼.005 and OR¼2.28; 95% CI, 1.12-4.63; P¼.02, respectively). Undertreatment was also associated with a significant increase in all-cause mortality (OR¼1.59; 95% CI, 1.14-2.21; P¼.006). Conclusion: Only half of all eligible patients with AF are prescribed oral anticoagulation in accordance with guideline recommendations. Guideline-adherent ATT significantly reduces the risk of stroke and improves survival. In accordance with current AF guidelines, stroke prevention with OAC should be the default therapy in patients with AF, unless a truly low risk of stroke (ie, congestive heart failure, hypertension, age !75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65-74 years, female sex category [CHA 2 DS 2 -VASc] score of 0 in men and 1 in women) is confirmed. 3, 4 Contemporary registry data show that approximately 5% of patients with AF have no risk factors for stroke, 5, 6 which indicates that risk stratification and OAC should be carefully and repeatedly reviewed in all patients with AF because risk factors can develop over time. Nonetheless, approximately onethird of patients with AF at risk for stroke are not given OAC but instead are treated with antiplatelet monotherapy or are left untreated, and approximately 50% of patients with no risk factors are unnecessarily prescribed OAC. 6, 7 
O ral anticoagulation (OAC) is the mainstay of effective stroke prevention in atrial fibrillation (AF) and reduces both stroke and mortality in AF. 1, 2 In accordance with current AF guidelines, stroke prevention with OAC should be the default therapy in patients with AF, unless a truly low risk of stroke (ie, congestive heart failure, hypertension, age !75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65-74 years, female sex category [CHA 2 DS 2 -VASc] score of 0 in men and 1 in women) is confirmed. 3, 4 Contemporary registry data show that approximately 5% of patients with AF have no risk factors for stroke, 5, 6 which indicates that risk stratification and OAC should be carefully and repeatedly reviewed in all patients with AF because risk factors can develop over time. Nonetheless, approximately onethird of patients with AF at risk for stroke are not given OAC but instead are treated with antiplatelet monotherapy or are left untreated, and approximately 50% of patients with no risk factors are unnecessarily prescribed OAC. Absolute OAC prescription rates, commonly reported by AF studies, 8 may be misleading because they may not reflect reallife eligibility for anticoagulation by failing to take into account the complexity of various clinical and patient-related factors affecting the final decision making on OAC prescription. For example, 1 in 10 patients with AF refuses to take OAC, 9 and the same proportion may have contraindications to anticoagulation. 10, 11 In addition, some patients with AF may require temporal combination antithrombotic treatment (ATT) (OAC þ antiplatelets) owing to acute vascular disease. 3, 4 The definition of guideline adherence may also vary, depending on applied stroke risk stratification schemes and guideline recommendations. 12, 13 Finally, indications for OAC in individual patients may change over time, making comparisons even more complex and difficult to interpret.
Previous reports on guideline adherence on OAC for stroke prevention in AF were based predominantly 14 or solely [15] [16] [17] on thromboembolic risk assessment, and patients were managed by cardiologists, mainly in hospitalbased or cardiology outpatient settings, often linked to university centers. Moreover, various combined end points and selected patient populations (ie, only patients at high risk for stroke) were used to assess the clinical relevance of guideline-recommended ATT. 14, 16, 17 We sought to provide herein a more comprehensive analysis of outcomes related to OAC guideline adherence, taking into account the aforementioned clinical and patient factors, and to assess the effect of guidelineadherent vs nonadherent thromboprophylaxis on "hard" clinical end points (stroke and death rates) in an unselected (ie, consecutive allcomers) contemporary, community-based AF population.
METHODS
The design of the Darlington AF Registry has been described previously. 18 In short, 11 primary care practices serving the population of 105,000 patients in Darlington, County Durham, United Kingdom, were involved. Consecutive all-comers with an established AF or atrial flutter diagnosis and a known vital status in March 2013 were eligible for inclusion.
Each primary care practice was equipped with the Guidance on Risk Assessment and Stroke Prevention in Atrial Fibrillation (GRASP-AF) tool. 10, 18 This electronic record interrogation software was designed to support primary care physicians in populationbased screening for stroke risk factors and to facilitate decision making for OAC prescription. Indeed, GRASP-AF is a free and easyto-use tool used to interrogate patient clinical data; it allows one to graphically display annual stroke risk. This measure helps clinicians identify patients with AF who may have a missing diagnosis code for AF, calculate the risk of stroke in patients with AF, identify patients at high risk for stroke who are not receiving OAC, calculate the number of strokes that a practice can expect in the next 12 months (given current levels of OAC), or help clinicians manage their patients with AF and highlight patients of concern or interest.
Because the GRASP-AF tool does not capture outcome events, additional searches of the primary care data set were performed to identify patients who experienced stroke or died during a 12-month observation period. Incident acute stroke was diagnosed only when there was a concordance between the clinical picture of cerebrovascular accident, physical examination, and cerebral imaging (computed tomography or magnetic resonance imaging). Cardiovascular death was defined as death resulting from 1 of the following conditions: cardiac (myocardial infarction, cardiac failure, cardiac arrest, coronary heart disease, ventricular tachycardia, or complete heart block), heart failure, stroke, pulmonary embolism or systemic thromboembolism, and intracranial bleeding. Every outcome event was manually reviewed and adjudicated. Read codes were used to capture and identify different types of strokes, comorbidities, medical treatments, contraindications to OAC/antiplatelets, and therapy decline. 18 
Stroke Risk
The CHA 2 DS 2 -VASc score was used to assess stroke risk. 19 As per the 2014 National Institute for Health and Care Excellence (NICE) guidelines, low risk was defined as a CHA 2 DS 2 -VASc score of 0 in men and 1 in women (1 point for sex category only); moderate risk as a CHA 2 DS 2 -VASc score of 1 in men;
and high risk as a CHA 2 DS 2 -VASc score of 2 or greater, regardless of sex. 3 Guideline Adherence in ATT Guideline adherence to ATT for stroke prevention was assessed against the 2014 NICE guidelines, including informed, shared decision making on therapy introduction. 3 Lack of guideline adherence was considered as either overtreatment (OAC overuse) or undertreatment (OAC underuse). Thus, the 3 patient categories were defined as follows. Guideline adherence was defined as OAC in moderate-and high-risk patients; combination therapy (OAC þ antiplatelets) in patients with acute vascular disease (ie, recent acute myocardial infarction); and no OAC in low-risk patients or in patients with reported contraindications to OAC or therapy decline. Undertreatment was defined as no OAC (but antiplatelet or no therapy) in moderate-or high-risk patients; no combination therapy (OAC þ antiplatelets) in patients with recent acute myocardial infarction; and no reported contraindications to OAC or therapy decline. Overtreatment was defined as OAC in lowrisk patients; OAC þ antiplatelet therapy in patients with no evidence of acute vascular disease; OAC in patients with reported contraindications to anticoagulation therapy; and antiplatelet therapy in patients with reported contraindications to both OAC and antiplatelet therapy.
Statistical Analyses
Categorical variables are reported as absolute frequencies and percentages, and continuous variables as mean AE SD. Baseline characteristics, stroke risk, and ATT, as well as outcome events, were tabulated in relation to the 3 categories (undertreatment, guideline adherence, and overtreatment). For the outcome events, 95% CIs were provided for the proportion of 1-year incident stroke rates and for the proportion of 1-year all-cause mortality rates, respectively.
Multivariable logistic regression analysis was performed to determine the independent predictors for 1-year stroke rates after adjustment for clinically relevant variables: age, hypertension, previous stroke, heart failure, and ATT (undertreatment, guideline adherence [as reference], and overtreatment). For all-cause death predictors, the multivariable regression analysis was performed after adjustment for the following variables: age, sex, hypertension, diabetes, previous stroke, heart failure, vascular disease, and ATT. The multivariable analysis was performed separately for the whole study population and for patients at high risk for stroke. All the statistical analyses were performed using IBM SPSS Statistics for Windows, Version 21.0 software (IBM Corp). Statistical significance was set at a 2-sided P<.05.
RESULTS
Overall, 2259 patients with AF (2.15% of the population) were identified, of which 1147 (50.8%) received guideline-adherent ATT, 816 (36.1%) were undertreated, and 296 (13.1%) were overtreated. The proportion of women was similar across the 3 study groups, at 46.1% on average. Undertreated patients were older (mean AE SD age, 77.0AE11.6 years) compared with guidelineadherent (75.3AE11.9 years) and overtreated (73.0AE14.6 years) patients, and the proportion of those 75 years and older was nonsignificantly different between the undertreated (n¼488; 59.8%) and guideline-adherent (n¼693; 60.4%) groups (P¼.78) ( Table 1) .
The highest prevalence of heart failure (n¼303; 26.4%), hypertension (n¼753; 65.6%), and diabetes mellitus (n¼275; 24.0%) was observed in the guidelineadherent group, whereas a history of stroke was more common in overtreated patients (n¼81; 27.4%) and least frequent in undertreated patients (n¼106; 13.0%). No significant differences were noted regarding stable and acute vascular disease (ie, acute myocardial infarction) among all groups (Table 1) .
Thromboembolic Risk and ATT
Stroke risk, as assessed by mean AE SD CHA 2 DS 2 -VASc score, was 3.4AE1.6 for undertreatment, 3.6AE1.7 for guideline adherence, and 3.4AE2.3 for overtreatment (Table 1 ). In the guideline-adherent cohort, 79.3% of patients (n¼910) were prescribed OAC (alone or combined with antiplatelets), 7.1% (n¼81) were given antiplatelet therapy, and 13.6% (n¼156) were untreated (no ATT). Oral anticoagulation was reported as contraindicated in 5.7% (n¼65) and declined in 9.9% (n¼113). In the undertreated cohort, 74.1% of patients (n¼605) received antiplatelet therapy and 25.9% (n¼211) were not treated, whereas in the overtreated group, 57.5% of patients (n¼170) were given OAC (either alone or combined with antiplatelets), 42.5% (n¼126) were given antiplatelets alone, and 41.2% (n¼122) had reported contraindications to OAC (Table 1) . Of 1080 patients who received OAC, 1050 (97.2%) were given a vitamin K antagonist (predominantly warfarin) and 30 (2.8%) were given a nonevitamin K OAC (NOAC). Antithrombotic drug choice in relation to guideline adherence and risk of stroke is summarized in Figure. Clinical Outcomes At 1 year, there were 32 incident strokes (3.9%; 95% CI, 2.8%-5.5%) for the undertreated group, 20 (1.7%; 95% CI, 1.1%-2.7%) for those guideline adherent, and 15 (5.1%; 95% CI, 3.1%-8.2%) for those overtreated; corresponding all-cause mortality rates were 115 (14.1%; 95% CI, 11.9%-16.7%), 81 (7.1%; 95% CI, 5.7%-8.7%), and 18 (6.1%; 95% CI, 3.9%-9.4%), respectively. The reasons for cardiovascular deaths were similar across the 3 study groups except that significantly more fatal strokes were observed in those undertreated (1.1%, n¼9) vs guideline-adherent patients (0.2%; n¼2; P¼.007). Details of 1-year outcomes in relation to guideline adherence (or not) for ATT are summarized in Table 2 .
Clinical outcomes by thromboembolic risk profile and applied ATT as per 2014 NICE guidelines 3 are shown in Table 3 . Of 67 acute strokes (3.0%), 66 (98.5%) were observed in high-risk patients (CHA 2 DS 2 -VASc score !2). For the high-risk cohort, 1-year stroke rates were 4.5% (95% CI, 3.2%-6.3%) (n¼32) for undertreatment, 1.9% (95% CI, 1.2%-2.9%) (n¼19) for guideline-adherence, and 7.2% (95% CI, 4.4%-11.6%) (n¼15) for overtreatment; corresponding all-cause, 1-year mortality rates were 16.1% (95% CI, 13.6%-19.0%) (n¼115), 8.0% (95% CI, 6.5%-9.8%) (n¼81), and 8.2% (95% CI, 5.2%-12.7%) (n¼17), respectively. One stroke event (0.6%) was noted in a low-risk patient, a man classified as guideline adherent (off anticoagulation). No 1-year stroke events or deaths were observed in patients at moderate risk for stroke (Table 3) . Table 4 ). For high-risk patients, both undertreatment and overtreatment were associated with a significant increase in 1-year stroke rates (OR¼2.32; 95% CI, 1.30-3.14; P¼.005 and OR¼2.28; 95% CI, 1.12-4.63; P¼.02, respectively), and undertreatment was also associated with a significant increase in 1-year all-cause mortality (OR¼1.59; 95% CI, 1.14-2.21; P¼.006) ( Table 4) . 
DISCUSSION
The principal findings of this study are that although 9 of 10 patients with AF managed in general practice are at high risk for acute stroke, only half are prescribed anticoagulation in line with current guideline recommendations. Most importantly, guideline-adherent ATT significantly reduced stroke rates and improved survival.
This study provides important insights into stroke risk profile and stroke prevention strategies in a contemporary, unselected primary care AF population in the United Kingdom. First, at least 1 nonesex-related risk factor for stroke (by CHA 2 DS 2 -VASc scheme and using the GRASP-AF tool) was captured in 92.5% of all-comers with AF. Contemporary global registry data, confined to new-onset AF only, demonstrate a very similar incidence, at 6.8%, 6 and European registries recruiting patients with AF managed by cardiologists indicate an even lower prevalence of lone AF, at 3.9%. 5 These observations highlight the clinical relevance of careful and repeated screening for even a single stroke risk factor in every patient with AF, with primary physicians playing a pivotal role given that stroke risk is not static but changes (increases) over time. 2, 20 Importantly, once the diagnosis of truly low risk has been proved, anticoagulation may be omitted. 3, 4 Indeed, in the 170 low-risk patients (CHA 2 DS 2 -VASc score of 0 in men and 1 in women) in the present analysis, only a single case of stroke occurred. However, nearly one-third of such low-risk patients were unnecessarily prescribed OAC. Similar overuse of stroke prevention therapies in patients with no stroke risk factors has been noted by previous reports. 6, 8 Importantly, current AF guidelines do not recommend treatment of low-risk patients because there is no evidence of benefit, but there may be increased risk of harm. 3, 4 Second, none of the 154 men at moderate risk for stroke (CHA 2 DS 2 -VASc score of 1) in the present study experienced an acute stroke or died during the 12-month observation period. The study was not powered to analyze whether the use of, or absence of, OAC affects outcomes in patients with only 1 risk factor for stroke. Annual stroke rates in untreated patients with only 1 risk factor for stroke (beyond sex) do vary among studies. [21] [22] [23] A recent Markov decision model suggests that stroke risk greater than 1.7% per year and greater than 0.9% per year warrants anticoagulation with warfarin and NOACs, respectively. 24 However, this model did not consider quality of anticoagulation control in warfarin users; with good-quality control, the 1.7% per year treatment threshold may even be lower. 25 For example, stroke/systemic thromboembolic events and mortality are high even in patients with only 1 stroke risk factor and despite OAC use. 25 Importantly, these event rates were significantly but inversely associated with time in therapeutic range (TTR), ranging from 3.5% in the lowest TTR quartile to only 0.7% in the highest TTR quartile. Of note, current AF guidelines already recommend OAC as a default therapy (whether with a NOAC or warfarin with TTRs as high as possible) in all patients with AF unless truly low risk is shown.
2-4
Third, we found herein that neither underuse nor overuse of ATT is beneficial for highrisk patients (CHA 2 DS 2 -VASc score !2). One-year stroke rates were lowest, at 1.9%, for guideline adherence, whereas the corresponding rates for undertreatment and overtreatment were 4.5% and 7.2%, respectively. Also, all-cause mortality was 2-fold higher in those nonadherent with recommendations. These findings highlight the importance of strict compliance with guideline recommendations (in this case, NICE) in real-life clinical practice. 3 Previous studies have also reported that guideline adherence is associated with better outcomes in patients with AF. [14] [15] [16] [17] In contrast to the present study, these patients were managed by either cardiologists [14] [15] [16] or internal medicine specialists, 17 where the prevalence of inpatients and participating university centers were high, as was the overall OAC uptake (up to 80%). 16 In addition, none of these studies considered contraindications to OAC or therapy decline (8.3% and 5.0%, respectively, in the present study), and only the EURObservational Research ProgrammeeAtrial Fibrillation (EORP-AF) Pilot General Registry corrected the definition of guideline adherence for the presence of acute vascular disease. 16 Importantly, definitions of clinical outcomes in previous studies did vary considerably. For example, the EORP-AF Registry did not show significantly lower rates of stroke alone for guideline adherence (as shown in the present analysis), but for a combined thromboembolic end point that comprised stroke, transient ischemic attack, acute coronary syndrome, percutaneous coronary intervention, cardiac arrest, peripheral embolism, and pulmonary embolism. 16 Moreover, the present study supports several important points regarding antithrombotic drug choice. First, aspirin is not effective and should not be used for stroke prevention in AF. 3, 4 One-year stroke rates in high-risk patients were even higher in those undertreated with antiplatelets vs no treatment. This is alarming given that more than one-third of eligible patients in the present analysis were not offered OAC, which not only significantly reduced stroke rates but was also a lifesaving treatment. Importantly, more recent data indicate that overall mortality reduction with an OAC even exceeds the reduction of strokerelated deaths only. 26 Second, 1 in 10 high-risk patients were overtreated, either with an OAC (combined with antiplatelets or alone) or with antiplatelets (reported contraindications to both OAC and antiplatelet therapy). Importantly, only a few patients with AF with recent acute myocardial infarction were guideline adherent on combination therapy, and most received either antiplatelet therapy only (undertreated cohort) or a combination therapy despite reported contraindications (overtreated cohort). Both regimens resulted in an excess in stroke rates, but allocation of many patients with vascular disease to the overtreated cohort creates a bias of their overall increased risk compared with guideline adherence. Even assuming that contraindications to OAC might have been overestimated by physicians, and some of these patients could actually be categorized as guideline adherent, the stroke rates of these patients would still remain high.
LIMITATIONS AND STRENGTHS
The major limitation of this analysis is the lack of overall bleeding risk and outcomes. Indeed, the GRASP-AF tool used for data collection in the Darlington Registry does not collect data on bleeding risk or events. Consequently, fatal and nonfatal hemorrhages were available only for patients with outcome events (stroke and death). Despite this limitation, we think that these findings are of clinical relevance for a variety of reasons. First, the GRASP-AF tool is part of the cornerstone National Health Service quality improvement program, which was primarily designed and implemented into practice to help primary care physicians tackle the nation's biggest killer, that is, stroke. Even more importantly, use of the GRASP-AF tool has been previously described as a means that could help prevent strokes in patients with AF. 18 Second, guideline recommendations on stroke prevention in AF highlight that bleeding risk per se should not be a reason to preclude or withhold stroke prevention strategies in patients with AF at risk for stroke. 3, 4 Indeed, absolute contraindications to OAC are rare, and if a patient truly cannot receive any of the available OACs, despite being at high risk for stroke, other options for stroke prevention could be considered (ie, left atrial appendage exclusion). 3, 4 If contraindications to OAC are not genuine, the priority should be correction of any potentially reversible risk factors for bleeding, but not withholding OAC use simply on a perceived high bleeding risk score. 27 Third, stroke and bleeding risk factors commonly overlap. 28 Thus, patients at highest risk for bleeding are usually also at highest risk for stroke, but the net clinical benefit of anticoagulation is positive and even greater in patients with both high stroke and bleeding risks, 29 that is, patients with frequent comorbid disease, very elderly and frail patients, 11, 30 or even those who have already bled (even intracranially). 31 Indeed, in contrast to stroke rates, we did not observe any differences in hemorrhagic strokes or intracranial bleeds among all 3 study groups.
Fourth, patients' views and preferences are also of great importance. Indeed, patients often view a stroke "as a fate worse than death" and may accept 4 major bleeds just to avoid 1 disabling stroke. 9 Thus, because the guidelinerecommended decision making on OAC prescribing is based on positive net clinical benefit when balancing the risk of stroke against the risk of bleeding complications (intracranial hemorrhage), 24 we do not think that providing the overall bleeding events (in addition to reported nonfatal intracranial bleeds and fatal hemorrhages) would substantially change our conclusions.
Our definition of adherence to guidelines may be inconsistent with previous articles, which reported absolute numbers/percentages of OAC use in patients with AF, and, thus, failed to reflect their real-life eligibility for anticoagulation (in particular, including patients' views and preferences). By doing so, previous reports showed more the effect of OAC use than the effect of guideline adherence on outcomes. Indeed, exclusion of contraindications to OAC or therapy decline assumes that 100% of patients must be given OAC (no exceptions), whereas the real-life data show that 12% of patients with AF refuse anticoagulation (so-called medication averse), even if the therapy were 100% effective for stroke prevention. 9 We assessed the quantity but not the quality of anticoagulation because neither international normalized ratios nor TTR values were available. Although this registry covered a broad population of more than 100,000 patients, it was confined to 1 UK region only, which may limit the generalizability of the findings. Because patient-specific data were analyzed in more detail only in patients with outcome events, baseline characteristics of the entire study population are limited. However, lack of patient selection allowed for evaluation of ATT patterns and outcomes in low-and moderate-risk cohorts. Unlike other studies, we also used only "hard" end points, which were confirmed by cerebral imaging and adjudicated. Nonetheless, we could not establish the cause of death with certainty in 45 patients (21.0% of the 214 deaths) because death certificates could not be retrieved. Thus, multivariable analysis of cardiovascular mortality predictors was not possible.
We based our definition of guideline adherence on the 2014 NICE guideline recommendations (which are applicable to our UKbased study), 3 which has similarity to the 2012 focused update of European Society of Cardiology guidelines on AF. 32 The present study validates the real-world application of these guidelines and the potential effect on stroke and mortality in patients with AF. CONCLUSION Despite 9 in 10 patients with AF being at high risk for stroke, only half of all eligible patients are prescribed anticoagulation in accordance with current guidelines. Guideline-adherent ATT significantly reduces the risk of stroke and improves survival at 1 year.
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